ANCONA, SILVIA
 Distribuzione geografica
Continente #
EU - Europa 4.675
NA - Nord America 3.413
AS - Asia 3.183
SA - Sud America 307
AF - Africa 90
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.693
Nazione #
US - Stati Uniti d'America 3.319
GB - Regno Unito 1.869
CN - Cina 1.091
SG - Singapore 918
IT - Italia 807
DE - Germania 767
HK - Hong Kong 322
RU - Federazione Russa 254
FR - Francia 234
BR - Brasile 233
SE - Svezia 195
VN - Vietnam 183
IN - India 157
NL - Olanda 140
BD - Bangladesh 125
FI - Finlandia 95
TR - Turchia 93
UA - Ucraina 93
KR - Corea 79
IE - Irlanda 77
CA - Canada 57
JP - Giappone 55
EU - Europa 46
ID - Indonesia 45
CI - Costa d'Avorio 40
DK - Danimarca 27
AR - Argentina 23
BE - Belgio 22
ES - Italia 22
AU - Australia 21
ZA - Sudafrica 20
CO - Colombia 19
IQ - Iraq 18
PK - Pakistan 17
GR - Grecia 12
MX - Messico 12
UZ - Uzbekistan 11
EC - Ecuador 10
PH - Filippine 10
PL - Polonia 10
AE - Emirati Arabi Uniti 8
TW - Taiwan 8
CH - Svizzera 7
CL - Cile 7
EG - Egitto 7
MA - Marocco 7
SA - Arabia Saudita 7
AT - Austria 6
HU - Ungheria 6
JM - Giamaica 6
NP - Nepal 6
RO - Romania 6
VE - Venezuela 6
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
KE - Kenya 5
MY - Malesia 5
SC - Seychelles 5
BB - Barbados 4
CR - Costa Rica 4
LT - Lituania 4
PY - Paraguay 4
BY - Bielorussia 3
IR - Iran 3
OM - Oman 3
PE - Perù 3
PT - Portogallo 3
AL - Albania 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GT - Guatemala 2
HN - Honduras 2
JO - Giordania 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
NO - Norvegia 2
PA - Panama 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AG - Antigua e Barbuda 1
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
GH - Ghana 1
IL - Israele 1
IS - Islanda 1
KY - Cayman, isole 1
MD - Moldavia 1
NC - Nuova Caledonia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PW - Palau 1
QA - Qatar 1
TG - Togo 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.738
Città #
Southend 1.724
Singapore 507
Ashburn 395
Milan 361
Hong Kong 291
Hanover 253
Chandler 241
San Jose 232
Dallas 223
Frankfurt am Main 201
Beijing 193
Seattle 149
Los Angeles 118
Santa Clara 110
Wilmington 103
Fairfield 91
Council Bluffs 90
Mountain View 80
Princeton 79
Hefei 72
Dublin 71
New York 70
Ann Arbor 68
Woodbridge 65
Bengaluru 59
Ho Chi Minh City 57
Houston 57
Hanoi 54
Dearborn 49
Lauterbourg 49
Jacksonville 47
Guangzhou 45
Redmond 45
Helsinki 44
Jinan 44
Moscow 43
Abidjan 40
Berlin 39
Nanjing 39
Jakarta 37
Phoenix 36
Buffalo 33
Shenyang 33
Seoul 32
Shanghai 29
Cambridge 28
Des Moines 28
Tokyo 27
Columbus 25
Munich 24
São Paulo 24
Toronto 24
Boardman 23
Medford 23
Sakarya 23
The Dalles 23
Changsha 21
Tianjin 21
Cangzhou 20
Brussels 19
Chicago 19
Hangzhou 19
Istanbul 19
Rome 19
Scranton 19
London 18
Serra 18
Fuzhou 17
Andover 16
Bogotá 15
Kiez 15
Zhengzhou 15
Atlanta 14
Eitensheim 14
Somerville 14
Hebei 13
Memphis 13
Nanchang 13
Naples 13
Ningbo 13
Nuremberg 13
San Diego 13
Ankara 12
Oegstgeest 12
Athens 11
Denver 11
Lappeenranta 11
Mumbai 11
Redwood City 11
Bathgate 10
Bologna 10
Brooklyn 10
Cagliari 10
Haiphong 10
Johannesburg 10
Saint Petersburg 10
Shenzhen 10
Sydney 10
Turin 10
Da Nang 9
Totale 7.581
Nome #
Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance 679
Anti-EGFR Antibody Efficiently and Specifically Inhibits Human TSC2-/- Smooth Muscle Cell Proliferation. Possible Treatment Options for TSC and LAM 469
Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way 445
STUDIO BIOCHIMICO E FARMACOLOGICO DI CELLULE MUSCOLARI LISCE ISOLATE DA TESSUTI DI PAZIENTI AFFETTI DA TSC2 E LAM. MODIFICAZIONI EPIGENETICHE DEL GENE TSC2 NELLA PATOGENENESI DELLA TSC E DELLA LAM. 351
The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells 327
Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis 301
Characterization of LAM/TSC cells isolated from patient chylous 287
A mouse LAM model by endonasal administration of human TSC2 deficient smooth muscle cells 282
Development of a LAM model by using human TSC2-/- cells derived from a renal angiomyolipoma : A pharmacological evaluation 273
LAM/TSC cell migration to uterus in an experimental model of lymphangioleiomyomatosis. Regulation by anti-epidermal growth factor receptor antibody and rapamycin 273
TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival 269
Pathogenesis and pharmacological evaluation of human TSC2 smooth muscle cells. Possible treatment options for TSC and lymphangioleiomyomatosis 267
Development of a cutaneous mouse model of TSC and LAM by injection of human tuberin-deficient cells : effects of chromatin remodelling agents 262
Un modello di linfangioleiomiomatosi con la somministrazione di cellule muscolari lisce umane TSC2-/- 261
Human smooth muscle TSC2-/- cells cause lymphangiogenesis-like lung destruction in nude mice. Pharmacological repair 258
Role of Prolactin Receptors in Lymphangioleiomyomatosis 243
Characterization of human TSC2 cells derived from a TSC/LAM patient chylous effusion 242
Development of a LAM model by using human TSC2 deficient smooth muscle cells derived from a renal angiomylipoma 241
Role of HMG-CoA reductase inhibitors in controlling TSC2-/- ASM cell growth and proliferation 237
Human LAM/TSC cells efficiently cause lung nodule formation and alveolar destruction. Pharmacological counteraction by modulation of mTOR activity 236
Promoter methylation of TSC2 gene is important for pathogenesis of TSC and LAM lesions 231
An epigenetic event may underlies the TSC features in TSC2 ASM cells 230
Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM 226
ROSUVASTATIN ACTING AS A DEMETHYLATING AGENT AFFECTS PROLIFERATION OF TSC2-/meth ASM CELLS 224
Glioblastoma multiforme in a child with tuberous sclerosis complex 218
MOTILITY AND INVASIVE PROPERTIES OF LAM/TSC CELLS FROM CHYLOUS OF A LAM/TSC PATIENT 214
KMT2A : umbrella gene for multiple diseases 214
Matrix methalloproteinase 2 and 7 are new targets in LAM and TSC-related disorders 208
Exploring the role of matrix metalloproteinases as biomarkers in sporadic lymphangioleiomyomatosis and tuberous sclerosis complex. A pilot study 208
Epigenetic disorders: Lessons from the animals-animal models in chromatinopathies 207
Differential modulation of matrix metalloproteinases-2 and-7 in LAM/TSC cells 207
LAM/TSC CELLS BEARING A TSC2 MUTATION SECRETE CHEMOKINES AND MATRIXMETHALLOPROTEINASES 202
p300 inhibition delays premature cellular senescence 200
LAM/TSC cells cause pulmonary nodule development by endonasal administration in nude mice 198
Tuberin deficiency for an epigenetic modification in LAM cells from chylous of a TSC2 patient 196
Direct and indirect pharmacological regulation of mTOR affects fate of LAM/TSC cells. Epithelial to mesenchymal transition features of LAM/TSC cells 191
Chromatin remodelling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of tuberin 189
Expanding the clinical spectrum of PPP3CA variants - alternative isoforms matter 187
LAM cells as potential drivers of senescence in lymphangioleiomyomatosis microenvironment 178
Dysfunction in IGF2R Pathway and Associated Perturbations in Autophagy and WNT Processes in Beckwith–Wiedemann Syndrome Cell Lines 176
Feasibility and acceptability of saliva-based testing for the screening of SARS-CoV-2 infection in prison 173
The role of NOTCH2 in the Extracellular vesicles mediated communication in Multiple Myeloma: a focus on angiogenesis and osteoclastogenesis 167
Senescence in lymphangioleiomyomatosis as a paradigm for the remodelling of lung microenvironment 163
The role of NOTCH2 in the extracellular vesicles-mediated angiogenesis and osteoclastogenesis in multiple myeloma 160
Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice 159
Molecular heterogeneity of TSC2-deficient cells 141
Pilocarpine inhibits Candida albicans SC5314 biofilm maturation by altering lipid, sphingolipid, and protein content 140
Primary TSC2-/meth Cells Induce Follicular Neogenesis in an Innovative TSC Mouse Model 133
Synthesis of amphiphilic hydantoin-based universal peptidomimetics as antibiotic agents 129
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients 119
Targeting extracellular vesicles in multiple myeloma: a new role for the Notch pathway 115
null 81
Gut Microbiota and Metabolic Modulation by Slow-Release Protein Substitutes in Phenylketonuria: Findings from the PREMP Study 68
ISOLATION AND CHARACTERIZATION OF SMOOTH MUSCLE-LIKE CELLS FROM A TSC2 RENAL ANGIOMYOLYPOMA. PROMOTER METHYLATION OF TSC2 GENE IS IMPORTANT FOR PATHOGENESIS OF TSC LESIONS 64
Tuberous sclerosis complex, epilepsy, and the microbiota-gut-brain axis: a pilot study of shared and divergent microbial signatures 41
Identification of ICAM-1–targeting DNA aptamers as a host-directed strategy to inhibit Human Rhinovirus infection 27
Totale 12.187
Categoria #
all - tutte 31.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.035


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021149 0 0 0 0 0 0 0 0 0 0 132 17
2021/2022952 117 48 49 61 53 61 94 66 109 96 69 129
2022/2023882 75 93 78 112 106 123 24 59 118 28 41 25
2023/2024740 25 30 82 48 175 51 44 51 31 42 69 92
2024/20251.684 55 138 57 173 155 73 103 136 89 182 182 341
2025/20263.751 373 305 465 297 328 214 556 164 376 267 406 0
Totale 12.187